One such mAb is urelumab (BMS-663513) [135], a fully human IgG4 CD137 agonist whose safety as monotherapy has been demonstrated [136] and currently is the subject of several combination studies for both solid and hematologic tumors, including a phase I trial with elotuzumab in MM (NCT02252263). Here, TNFRSF9 is linked to Miyoshi myopathy.